gms | German Medical Science

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Deutsche Gesellschaft für Infektiologie,
Deutsche AIDS-Gesellschaft,
Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit,
Paul-Ehrlich-Gesellschaft für Chemotherapie

23.06. - 26.06.2010, Köln

Low rate of Immunoresponse to the novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine in HIV-1 infected patients

Niedrige Rate des Impfansprechens auf die neue, inaktivierte, adjuvantierte, pandemische H1N1 influenza Impfung bei HIV-1 infizierten Patienten

Meeting Abstract

  • M. Bickel - Goethe Universität, Infektiologie, Frankfurt, Germany
  • I. Wieters - Goethe Universität, Infektiologie, Frankfurt, Germany
  • N. von Hentig - Goethe Universität, Infektiologie, Frankfurt, Germany
  • P. Khaykin - Goethe Universität, Infektiologie, Frankfurt, Germany
  • G. Nisius - Goethe Universität, Infektiologie, Frankfurt, Germany
  • A. Haberl - Goethe Universität, Infektiologie, Frankfurt, Germany
  • C. Stephan - Goethe Universität, Infektiologie, Frankfurt, Germany
  • H.W. Doerr - Goethe Universität, Medizinische Virologie, Frankfurt, Germany
  • H.R. Brodt - Goethe Universität, Infektiologie, Frankfurt, Germany
  • R. Allwinn - Goethe Universität, Medizinische Virologie, Frankfurt, Germany

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010). Köln, 23.-26.06.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocINF 20-5

DOI: 10.3205/10kit043, URN: urn:nbn:de:0183-10kit0432

Published: June 2, 2010

© 2010 Bickel et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: To determine immunoresponse after single intramuscular dose of the novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009(H1N1)v-like strain (X-179 A) in HIV-1 infected patients. Response rates to this vaccine in the general population are reported to be 98–100%. (ClinicalTrials.gov Identifier: NCT01017172).

Patients and methods: Adult HIV-1 infected individuals scheduled for H1N1 vaccination where eligible to participate in this study. Serum samples where taken before and 21 days after vaccination. Antibody titers were determined by H1N1 hemagglutination inhibition assay (HAI), clinical and HIV related data were extracted from the charts. Response to vaccination was defined by an HAI titer ≥1:40 and a least four fold increase in antibody titer post vaccination.

Results: Up to now 160 pts (125 m/35f) were analysed. Before vaccination 23 pts (14.4%) and 22±3 days after vaccination 120 pts. (75%) had a HAI titer ≥1:40. Response to vaccination was found in 110 (69%). Reponders tended to be younger (45.1±10.0 vs 48.8±11.3 years; p=0.04), had a higher CD4 cell count (532±227 vs 475±281 cells/µl; p=0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs 8%; p=0.009) when compared to non responders. No other significant differences were found comparing: the rates of pts with AIDS, on HAART, HIV RNA PCR < 50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, hepatitis B or C between responders and non responders.

Conclusion: Response rates to a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV infected patients are lower as compared to the general population. Further studies are needed to investigate whether a second dose will increase response rates.